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Human immunodeﬁciency virus type 1 (HIV-1)–speciﬁc
T cell responses were characterized in a blinded study in-
volving infected individuals and their seronegative exposed
uninfected (EU) partners from Lusaka, Zambia. HIV-1–
speciﬁc T cell responses were detected ex vivo in all infected
individuals and ampliﬁed, on average, 27-fold following
in vitro expansion. In contrast, no HIV-1–speciﬁc T cell re-
sponses were detected in any of the EU partners ex vivo or
following in vitro expansion. These data demonstrate that
the detection of HIV-1–speciﬁc T cell immunity in EU in-
dividuals is not universal and that alternative mechanisms
may account for protection in these individuals.
Identifying the correlates of protective human immunodeﬁ-
ciency virus type 1 (HIV-1) immunity is a priority for HIV-1
research and vaccine development. The presence of HIV-1–
speciﬁc T cell immune responses has been described in HIV-1–
exposed but persistently uninfected individuals (EUs) and has
been suggested to represent a potential correlate of protection in
these individuals, as reviewed in [1]. However, the results from
studies aimed at identifying HIV-1– or simian immunodeﬁ-
ciency virus–speciﬁc T cell immunity in EUs have varied, and
virus-speciﬁc CD81 T cell responses were either of low mag-
nitude and breadth, only transiently detectable, not protective,
or not readilyidentiﬁabletothe minimal T cellepitopes targeted
in most of the published studies [2–6].
Uninfected partners of HIV-1–infected individuals are at high
risktobeexposedtoandeventuallyinfectedwithHIV-1.Cohort
studies in HIV-discordant couples have shown that joint testing
and counseling prompts a marked increase in reported condom
use and an estimated two-thirds reduction in transmission [7].
Nonetheless, residual annual infection rates of 7 cases per 100
couples per year among HIV-discordant couples reﬂect ongoing
exposure [7, 8] and are .14-fold the infection rates among
couples with 2 HIV-negative partners [9].
To determine whether HIV-1–speciﬁc T cell responses were
present in the exposed seronegative partners of adults with
chronic HIV-1 clade C infection, we performed a blinded study
involving 61 individuals enrolled in Lusaka, Zambia, including
29 EUs.
METHODS
Subjects
A total of 61 individuals enrolled at the Zambia Emory HIV
Research Project (ZEHRP) in Lusaka, Zambia, were included in
this study. These included 15 low-risk HIV-1–uninfected men
and women from 8 concordant HIV-1–negative couples, 14
HIV-1–infected index partners, and 32 partners from 41 dis-
cordant couples initially classiﬁed as HIV-1 negative. All HIV-
positive individuals were antiretroviral therapy naive. High-risk
exposure of HIV-1–negative individuals was deﬁned as report-
ing regular unprotected sex (at least once every 3 months) with
an HIV-1–positive spouse, and low-risk exposure was deﬁned as
being in a monogamous marriage with an HIV-1–negative
partner. Of the 32 partners in HIV-discordant couples initially
classiﬁed as HIV-1–negative, 3 seroconverted 1–5 months prior
to phlebotomy and are classiﬁed as HIV-1–positive for the
analysis. The remaining 29 individuals were classiﬁed as EUs at
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converted within 1–8 months after the initial phlebotomy. The
high rate of HIV-1 seroconversion (7 of 32 individuals within 1
year) reﬂects the high exposure rate in this cohort. Additional
data to estimate exposure were available for 28 of 29 EUs.
Among those individuals, 23 couples (82%) reported un-
protected sex,17(61%)hadgenitalinﬂammation,20(71%)had
genital ulceration, 16(57%) had spermdetected onvaginal swab
samples, 5 (18%) had trichomonas detected on vaginal swab
samples, and 8 had a pregnancy during the 2-year study period.
The respective local institutional review boards approved
the study, and all experiments were performed while inves-
tigators were blinded for the HIV-1 and exposure status of the
participants.
Assessment of HIV-1-Specific T Cell Responses Using Ex Vivo
Enzyme-linked Immunosorbent Spot (ELISPOT) Assays
ELISPOT assays were performed using overlapping 13–18 mer
peptides (overlap 10aa) spanning the expressed HIV-1–clade C
consensus sequence of Gag, Nef, Rev, and Tat [10]. Fresh
peripheral blood mononuclear cells (PBMCs) were plated in 96-
well plates precoated with anti–interferon (IFN)–c monoclonal
antibody. PBMCs were added at 50,000–100,000 cells/well in
100 lL of R10 medium (Roswell Park Memorial Institute
1640, 10% fetal calf serum, 10 mM HEPES buffer, 2 mM L-
glutamine, and 50 U penicillin-streptomycin per mL). Plates
were incubated overnight at 37C, 5% CO2, and developed
as described [10]. Wells containing PBMCs and R10 were
used as negative controls in triplicate. Wells containing PBMCs
andphytohemagglutininservedaspositivecontrols.Numbersof
spots per well were counted using an automated ELISPOT
plate reader, and the number of speciﬁc T cells was calculated
by subtracting the negative control values. Background was
,30/10
6 PBMCs (3spots/well at 100,000 PBMCs/well) in all
cases. Responses were regarded as positive if at least 3 times the
mean number of spot forming cells (SFC) in the 3 control wells
and .50 SFC/10
6 PBMCs.
Flow-Based Intracellular Cytokine Staining (ICS)
For 16 individuals, pools of overlapping peptides (OLP) span-
ning Gag, Nef, and Rev/Tat were used as antigens for ﬂow-based
ICS,which wasperformeddirectly exvivoandafter 10daysofin
vitro stimulation. PBMCs were incubated with peptide pools,
anti-CD28,andanti-CD49dantibodiesfor1hat37C,5%CO2,
followed by 5 h in the presence of Brefeldin-A. Cells were
stained with surface antibodies (CD3, CD4, CD8; BD) at 4Cf o r
30 min. After washing, cells were ﬁxed and permeabilized
using the Caltag Cell Fixation and Permeabilization kit ac-
cording to the manufacturer’s protocol. ICS was performed
using anti-IFN-c–speciﬁc monoclonal antibodies, and cells were
analyzed on a FACS Calibur ﬂowcytometry instrument using
Fluorescein isothiocyanate, Phycoerythrin, Peridinin chlorphyll
protein, and Allophycocyanin as ﬂuorescent parameters. Con-
trol conditions were established using autologous PBMCs,
which had not been stimulated with peptide but which had
otherwise had been treated identically. PBMCs stimulated with
Phorbol-12-myristat-13-acetat/Ionomycin were used as positive
controls.
Antigen-Specific In Vitro T Cell Expansion
For antigen-speciﬁc in vitro expansion of T cells, 5–10 3 10
6
fresh PBMCs were incubated with pools of overlapping peptides
spanning Gag, Nef, and Rev/Tat at a ﬁnal concentration of 2 lg/
mL/peptide. Cell cultures were expanded and maintained in R10
medium supplementedwith50U/mLrIL-2 for 10daysandthen
submitted to ﬂow-based ICS as described above.
RESULTS
HIV-1–speciﬁc T cell responses from all 61 study participants
were analyzed prior to unblinding for HIV-1 infection status.
HIV-1–speciﬁc T cell responses were initially assessed utiliz-
ing fresh PBMCs in an IFN-c ELISPOT assay with overlapping
peptides spanning HIV-1 clade C Gag, Nef, Rev and Tat, as
described above [10]. In 2 samples (classiﬁed as HIV-1–neg-
ative low-risk after unblinding), the initial ELISPOT assays
did not pass quality control because of high background ac-
tivity (.50 SFC/10
6 PBMCs) in the negative control wells.
However, ELISPOT assays in these 2 individuals were repeated
from frozen PBMCs and included in the analysis. After un-
blinding of the HIV-1 status for the 61 subjects (15 low-risk
HIV-1–negative individuals, 17 HIV-1–positive individuals,
and 29 EUs) strong detectable HIV-1–speciﬁc T cell responses
directed against Gag, Nef, Rev, and Tat were found in all 17
HIV-1–infected individuals (including the 14 index case pa-
tients and the 3 individuals who were infected 1–5 months
prior to enrolling into the study), ranging from 700 to 9400
SFC per million PBMCs (median value, 1700 SFC per million
PBMCs; Figures 1A and 1C). In these infected individuals,
HIV-1–speciﬁc T cell responses were preferentially directed
against Gag and Nef (Figure 1C), in concordance with pre-
vious studies [10]. No HIV-1–speciﬁc T cell responses were
detected in the 15 HIV-1–negative, low-risk individuals.
Among the 29 high-risk EU subjects, HIV-1–speciﬁc T cell
responses were detected in only 1 individual (AD45; Figure
1A). This study participant was classiﬁed as HIV-1 seroneg-
ative during the initial blood draw on the basis of a serological
p24 enzyme-linked immunosorbent assay (ELISA) result that
was negative for HIV 1 month prior to phlebotomy. However,
the patient was in fact identiﬁed and assayed during acute
HIV-1 infection with subsequent HIV-1 seroconversion (the
patient’s ﬁrst positive HIV ELISA result was obtained 7 weeks
after phlebotomy). Primary HIV-1 infection at time of the T
cell assays was documented by outgrowth of replication
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however, unfortunately, no plasma was available to quantify
the actual HIV viral load. No HIV-1–speciﬁc T cell responses
were detected in any of the remaining 28 HIV-1–seronegative
high-risk EUs (Figures 1A and 1B), including 1 additional
individual with HIV-1 seroconversion within 2 months after
phlebotomy. Taken together, these data demonstrate the ab-
sence of detectable ex vivo HIV-1 Gag–, HIV-1 Nef–, HIV-1
Rev–, and HIV-1 Tat–speciﬁc T cell responses in exposed,
uninfected partners of HIV-1–infected individuals using an
IFN-c ELISPOT assay that had 100% sensitivity to detect vi-
rus-speciﬁc T cell responses in individuals with chronic HIV-1
infection in this study, as well as in the 1 individual with acute
HIV-1 infection, when cytotoxicTl y m p h o c y t er e s p o n s e sa r e
generally of low magnitude and breadth [11].
Ex vivo frequencies of HIV-1–speciﬁc T cell responses can
be of low magnitude in EUs, as described in previous studies
[1, 5]. We therefore used an in vitro expansion protocol on
fresh samples obtained from a subset of 16 study subjects (4
EUs, 4 low-risk HIV-1–negative individuals, and 8 HIV-1–
infected individuals) during a second blood draw 12 months
later, prior to unblinding, to expand HIV-1–speciﬁc T cells,
using Gag, Nef, Rev, and Tat pools of overlapping peptides as
described above. In the 8 HIV-1–infected individuals studied,
HIV-1–speciﬁc CD81 T cell responses were detectable in all
individuals directly ex vivo, with the total response ranging
from 0.34% to 4.06% of CD81 T cells (median value, 1% of
CD81 T cells) (Figures 2A and 2E). Ex vivo frequency of
CD81 T cells directed against Gag ranged from 0.4% to
3.5%, Nef-speciﬁc CD81 T cells ranged from 0.3% to 2.7%,
and CD81 T cells directed against Rev/Tat ranged from 0.2%
to 1.5%. These virus-speciﬁc CD81 T cell responses were
expanded signiﬁcantly following in vitro stimulation (me-
dian increase, 27-fold; range, 9–69-fold; P 5 .002), reaching
median frequencies of 33% of total CD81 T cells (range, 6%–
80%) (Figures 2B and 2E). Despite this signiﬁcant expansion
of HIV-1–speciﬁc CD81 T cells in vitro in infected in-
dividuals, no HIV-1–speciﬁc CD81 T cell responses above
background were detected in the 8 HIV-1–negative in-
dividuals (4 low-risk and 4 high-risk seronegative subjects)
either when tested directly ex vivo or following the in vitro ex-
pansion (Figures 2C, 2D, and 2E). The 4 high-risk seronegative
individuals reported condom use and exposure histories similar
to those reported by the overall group of 28 EUs. Three of the 4
couples reported unprotected sex, 1 of 4 EUs had genital in-
ﬂammation, 2 of 4 EUs had genital ulceration, and 2 of 4 EUs
had sperm detected on vaginal swab samples.
DISCUSSION
This study, which was performed entirely blinded with pre-
established criteria for assay positivity, demonstrates a lack of
Figure 1. Human immunodeficiency virus type 1 (HIV-1)–specific T cell
responses were measured in blinded fashion by ex vivo interferon–c
enzyme-linked immunosorbent spot (ELISPOT) assay in HIV-1 seropositive
and exposed seronegative individuals. ELISPOT data were available for all
61 study subjects. Panel A shows strong Tcell responses to HIV-1 clade C
Gag, Rev, Tat, and Nef overlapping peptides in all individuals identified as
known HIV-seropositive study participants after unblinding. Results are
shown as total magnitude of SFC/10
6 peripheral blood mononuclear cells
(PBMCs). In contrast, study subjects who were identified as HIV-1
seronegative at study entry (including 28 high-risk exposed uninfected
[EU] and 15 low-risk HIV seronegative control subjects) did not have
detectable HIV-1 clade C–specific Tcell responses ex vivo. One individual
(AD45; arrow) who was classified as EU at study entry by an enzyme-
linked immunosorbent assay (ELISA) result that was negative for HIV at 1
month prior to phlebotomy had detectable T cell responses by ex vivo
ELISPOT. This individual had a positive HIV ELISA result at 7 weeks after
phlebotomy and was sampled and assayed during acute HIV infection
(confirmed by isolation of replication-competent virus from a PBMC
sample from same time point as the ELISPOT assay; no plasma was
available for HIV viral load quantification). Panels B and C show
representative examples of ELISPOTscreenings with overlapping peptides
spanning HIV-1 clade C Gag, Rev, Tat, and Nef in an HIV-1–seropositive
individual and a high-risk exposed seronegative individual, respectively.
All experiments were performed blinded. Positive responses were defined
as at least 3 times the number of SFCs in the control wells and had to be
.50 SFC/10
6 PBMCs [10].
260 d JID 2011:203 (15 January) d Addo et al.Figure 2. Large expansion of human immunodeficiency virus type 1 (HIV-1)–specific CD81 T cell responses measured by flow cytometry in HIV-1–
positive (but not HIV-1 high- or low-risk seronegative) individuals after HIV-1–specific in vitro stimulation and expansion. HIV-1 clade C Gag, Rev, Tat, and
Nef responses were measured by flow cytometry ex vivo and after 10-day in vitro peptide-specific stimulation with pools of overlapping peptides in
a subset of HIV-positive (n 5 8) and HIV-seronegative individuals (n 5 8), including 4 high-risk and 4 low-risk EU. Representative examples of the total
HIV-1–specific intracellular interferon–c response ex vivo (A and C) and after 10-day stimulation (B and D) for an HIV-1–positive individual (A and B) and
an exposed HIV-1–uninfected individual (EU) (C and D) are shown. Panel E shows the summary for the total HIV-1–specific T cell responses for 16
individuals tested pre- and post-stimulation as measured by flow cytometry. HIV-1–specific CD81 Tcell responses were detectable in all HIV-1–infected
individuals directly ex vivo, with the total response ranging from 0.34% to 4.06% (median response, 1%). These virus-specific CD81 T cell responses
expanded significantly after in vitro stimulation (median increase, 27-fold; range, 9–69-fold; P 5 .002), reaching median frequencies of total HIV-1–
specific CD81 Tcells of 33% (range, 6%–80%). No HIV-1–specific Tcell responses above background were detected by intracellular cytokine staining in
the 8 HIV-1–negative individuals (4 low-risk and 4 high-risk seronegative subjects) who were tested directly ex vivo or following the in vitro expansion (C,
D, and E), as represented by the graph line overlying the x-axis, showing no change between before and after stimulation (E).
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partners of HIV-1–infected individuals in Lusaka, Zambia.
Several mechanisms might account for the lack of detectable
virus-speciﬁc T cell responses. Sexual exposure to HIV-1 is
difﬁcult to quantify and validate, and exposure in our study
subjects might have been low. However, epidemiological data in
this cohort strongly suggest ongoing regular HIV-1 exposure [7,
8], and condom use, exposure frequencies, and genital exami-
nation ﬁndings, as well as the acquisition of HIV-1 in 7 of 32
high-risk individuals enrolled within months of phlebotomy,
conﬁrm this ﬁnding. Despite counseling for condom use, HIV-1
incidence rates in this cohort of HIV-discordant couples have
remained high (7%–8% per year), as have the rates of preg-
nancies (22% per year) [12]. Overall, these data strongly suggest
high HIV-1 exposure rates in the HIV-1–negative partners.
An alternative explanation for the lack of detectable HIV-1–
speciﬁc T cell responses can be low sensitivity of the assays used
to detect low-frequency HIV-1–speciﬁc T cell responses. Pre-
vious studies have used ex vivo ELISPOT and ﬂow cytometry
assays to detect immune responses in EU, and using these
same assays, we detected HIV-1–speciﬁc T cell responses in all
HIV-1–infected individuals, including an individual with pri-
mary HIV-1 infection, when HIV-1–speciﬁc T cell immunity is
generally low [11]. We furthermore enhanced the sensitivity of
the assays used in this study by a speciﬁc in vitro expansion of
HIV-1–speciﬁc T cells following stimulation with HIV-1 anti-
gens. This in vitro expansion resulted in a median 27-fold in-
crease in HIV-1–speciﬁc T cell responses in infected individuals
but no detectable T cell responses in EUs. However, we cannot
exclude the possibility that differences in the experimental ap-
proaches used here and in previously published studies [13]
might have accounted for some of the divergent results
reported in the literature in terms of presence or absence of
HIV-1–speciﬁc T cell responses in EUs. However, overall, these
data suggest that the absence of detectable responses was not
a consequence of lack of exposure or of the sensitivity of the
assays used.
In conclusion, we here report the absence of detectable
HIV-1–speciﬁc T cell responses in a cohort of HIV-1–exposed
but persistently uninfected partners of HIV-1–infected in-
dividuals from a well-established and well-characterized
Zambian cohort. These data demonstrate that the detection of
virus-speciﬁc immunity in EUs is not universal, as suggested
by an increasing body of data [5, 6], and that other mecha-
nisms than HIV-1–speciﬁc T cell immunity might account for
the protection of EU individuals [14, 15]. Additional blinded
prospective studies in large cohorts of EUs, including studies
that involve sampling at mucosal sites of exposure, are needed
to systematically identify the correlates of protection from
infection in these individuals.
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